Hennion & Walsh Asset Management, Inc. Karyopharm Therapeutics Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$2.84 - $3.92 $13,572 - $18,733	-4,779 Reduced 3.31%	139,574 $543,000
Q4 2022 Jan 12, 2023	SELL	$2.48 - $5.93 $327,531 - $783,169	-132,069 Reduced 47.78%	144,353 $491,000
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $41,766 - $59,579	-10,237 Reduced 3.57%	276,422 $1.51 Million
Q2 2022 Jul 19, 2022	SELL	$4.15 - $8.37 $411,588 - $830,119	-99,178 Reduced 25.7%	286,659 $1.29 Million
Q1 2022 Apr 26, 2022	SELL	$5.91 - $14.38 $46,423 - $112,954	-7,855 Reduced 2.0%	385,837 $2.84 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $8.61 $71,804 - $118,663	-13,782 Reduced 3.38%	393,692 $2.53 Million
Q3 2021 Nov 12, 2021	BUY	$4.45 - $10.63 $140,958 - $336,715	31,676 Added 8.43%	407,474 $2.37 Million
Q2 2021 Aug 13, 2021	BUY	$8.11 - $11.11 $882,611 - $1.21 Million	108,830 Added 40.77%	375,798 $3.88 Million
Q1 2021 May 17, 2021	BUY	$9.85 - $17.69 $2.63 Million - $4.72 Million	266,968 New	266,968 $2.81 Million

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $53.5M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.